Anthem Biosciences · NSE: ANTHEM · BSE: 544449
Q2 FY26 results · Jul–Sep 2025
Anthem Biosciences reported revenue from operations of ₹550.03 crore and net profit of ₹173.43 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 550.03 | — | — | 540.21 | +1.8% |
| Other income | 48.23 | — | — | 22.81 | +111.4% |
| Total income | 598.26 | — | — | 563.02 | +6.3% |
| Profit before tax | 229.60 | — | — | 186.25 | +23.3% |
| Net profit for the period | 173.43 | — | — | 135.79 | +27.7% |
| EPS, basic (₹) | 3.09 | — | — | 2.43 | +27.2% |
| Net margin (%) | 31.5 | — | 25.1 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 552.23 | — | — | 538.01 | +2.6% |
| Other income | 53.80 | — | — | 27.73 | +94.0% |
| Total income | 606.02 | — | — | 565.74 | +7.1% |
| Profit before tax | 253.30 | — | — | 198.94 | +27.3% |
| Net profit for the period | 198.43 | — | — | 148.34 | +33.8% |
| EPS, basic (₹) | 3.54 | — | — | 2.65 | +33.6% |
| Net margin (%) | 35.9 | — | 27.6 |
Consolidated
- Filed with BSE
- 09 Nov 2025, 16:04 IST
- Board meeting
- 08 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2025, 16:04 IST
- Board meeting
- 08 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE